Shenzhen Kangtai Biological Products Co (300601) Fair Value & Analysis
Healthcare · CN · Market cap 13.0B CNY
Analysis
Shenzhen Kangtai Biological Products Co (300601) currently trades at ¥11.44, while our model-based Fair Value estimate is ¥1.48 — implying the stock looks roughly 87.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria, tetanus, and acellular pertussis combined vaccine, adsorbed; rabies vaccines (human diploid cell, freeze-dried) for human use; haemophilus influenzae type b conjugate vaccines; measles and rubella combined vaccines (live); SARS-CoV-2 vaccines (vero cell, inactivated); and COVID-19 vaccines (ChAdOx1-S recombinant). It also develops measles, mumps, and rubella vaccines; DTaP-Hib-IPV combined vaccines, 4-valent influenza (split) vaccines, and poliomyelitis vaccines (vero cells, inactivated for the Sabin strain). I…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.